Leaflet POMALIDOMIDA STADA 3mg capsules


Indicated for: hematologic malignancies

Substance: pomalidomide (immunomodulator)

ATC: L04AX06 (Antineoplastic and immunomodulating agents | Immunosuppressants | Other immunosuppressants)

Pomalidomide is an immunomodulatory agent used in the treatment of relapsed or refractory multiple myeloma. It works by stimulating the immune system and inhibiting tumor cell growth.

The medication is taken orally, as directed by a doctor, usually once daily in treatment cycles. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as anemia, fatigue, or infections. It is important to inform the doctor of any unusual symptoms.

Common side effects include anemia, fatigue, and neutropenia. In rare cases, severe reactions such as deep vein thrombosis or allergic reactions may occur. Patients should be informed of these risks before use.

General data about POMALIDOMIDA STADA 3mg

  • Substance: pomalidomide
  • Date of last drug list: 01-05-2026
  • Commercial code: W71170002
  • Concentration: 3mg
  • Pharmaceutical form: capsules
  • Quantity: 21
  • Product type: generic
  • Price: 2753.40 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: STADA ARZNEIMITTEL GMBH - AUSTRIA
  • Holder: STADA ARZNEIMITTEL AG - GERMANIA
  • Number: 16066/2025/02
  • Shelf life: 4 years

Concentrations available for pomalidomide

  • 1mg
  • 2mg
  • 3mg
  • 4mg

Compensation lists for POMALIDOMIDA STADA 3mg STADA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

2753.40 RON

2753.40 RON

0.00 RON